Selank started as an immunology project at the Institute of Molecular Genetics of the Russian Academy of Sciences. Researchers took tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the heavy chain of immunoglobulin G that regulates immune function — and extended it with a Pro-Gly-Pro tripeptide at the C-terminus to improve metabolic stability.
Nobody predicted what they got: a compound that not only preserved tuftsin's immunomodulatory properties but crossed into the central nervous system and produced anxiolytic effects comparable to benzodiazepines — without any of the characteristic benzodiazepine side effects. No sedation. No amnesia. No dependence or withdrawal in any animal model tested.
Selank was subsequently approved in Russia and Ukraine for generalised anxiety disorder (GAD) and neurasthenia. The human trial data — while limited and mostly Russian — is some of the most concrete clinical evidence for any peptide in this book's cognitive section. A direct head-to-head comparison against an approved benzodiazepine in 62 anxiety patients is a meaningful data point.
Selank's pharmacology is unusually broad for a heptapeptide. The mechanisms are inter-related rather than independent, and together produce a profile that is distinct from both benzodiazepines and classic nootropics.
Selank has a devoted community following built specifically on the absence of benzodiazepine side effects. It is used most commonly by people dealing with performance anxiety, social anxiety, high-stress periods, or those seeking to address anxiety without pharmaceutical dependence risks. It is frequently stacked with Semax — the pairing covers the anxiety-focus spectrum simultaneously.
Selank is an anxiolytic nootropic that modulates GABA, serotonin, and immune function. Its synergies support the anxiety-reduction and cognitive-stability pathways it works through.
Disclaimer: These recommendations are educational and based on the known mechanisms of each compound. Individual responses vary. Consult a qualified healthcare provider before changing your supplement or exercise regimen, particularly when using experimental peptides.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
Selank has one of the most compelling evidence profiles in the cognitive peptide space — not because the data is abundant, but because what exists is unusually direct. A 62-patient head-to-head trial against an approved benzodiazepine, showing comparable anxiolytic efficacy with additional cognitive benefits and no side effect burden, is a genuine data point that most peptides in community use cannot match.
The profile is further supported by clean mechanistic data across five pathways, an approved regulatory status in Russia, and the most consistently positive community reports in the cognitive peptide space. Its safety signal is also unusually clean — rapid clearance, no dependence, no antibody formation.
The caveats are the same as for most Russian-developed compounds: the best clinical data is from Russian groups, independent Western trials haven't been done, and long-term safety is understudied. But within those constraints, Selank stands as possibly the best-evidenced anxiolytic peptide in existence.